EMERGENCY MEDICINE · UK EDITION
EM Evidence Rundown
Week of 9 April 2026 | Issue #5
Jake Turner
Curated with the assistance of AI (Perplexity). All content editorially reviewed.
A landmark HSSIB report lays bare the legal vacuum at the heart of mental health crisis care in EDs — staff are routinely forced to break the law to protect patients. The OPTION trial opens a potential thrombolysis window to 24 hours for selected non-LVO stroke. LEGEND's stepped-wedge RCT shows a single ultra-low troponin slashes ED length of stay by 3.6 hours. And UKHSA has raised the UK importation risk for mpox clade Ib to HIGH with 45 cases confirmed. Elsewhere: LAAC fails its non-inferiority test against medical therapy in AF, beta-blockers after MI come under scrutiny, and geriatric EM gets its first GRADE-methodology guidelines.
WHAT'S INSIDE
15 main items · 3 paediatric items · 8 quick hits · 3 trials to watch
Top quality scores this week: OPTION trial (14), LEGEND trial (14), HSSIB mental health report (14), JAMA paediatric concussion SR (13), UKHSA mpox Ib alert (13)
EVIDENCE TAG LEGEND
THIS WEEK'S CONTENTS
Guidelines & UK Updates
1. HSSIB Mental Health Crisis Care in EDs — No Lawful Power to Detain (Safety Recs R/2026/082–083) 2. UKHSA Mpox Clade Ib — UK Importation Risk Elevated to HIGH, 45 Cases 3. NHS England Martha's Rule — Mandatory in NHS Standard Contract 2026/27 by March 2027 4. RCEM Scotland A&E Crisis — Record 12-Hour Waits, 7,967 Patients in February
Key Journal Articles & Trials
5. OPTION Trial (JAMA) — Tenecteplase 4.5–24h in Non-LVO Stroke 6. LEGEND Trial (Ann Emerg Med) — hs-Troponin LoD Strategy Reduces ED LOS by 3.6h 7. PreMeFen Trial (Lancet) — Methoxyflurane Non-Inferior to IV Morphine Prehospital 8. SMART-DECISION (NEJM) — Stopping Beta-Blockers >1yr Post-MI is Safe 9. CLOSURE-AF (NEJM) — LAAC Not Non-Inferior to Medical Therapy in AF 10. SPOTLESS-2 (Acad Emerg Med) — Peripheral Vasopressors Safe Prehospital, 93.4% Event-Free 11. BMJ Airway Review — Video Laryngoscopy Over Direct Laryngoscopy for RSI
Paediatric EM (Dedicated Section)
12. JAMA Rational Clinical Exam — Paediatric Concussion Diagnosis (LR Data) 13. Cochrane — Neonatal Resuscitation Training Reduces 24h Mortality (RR 0.73)
14. AHA Statement — Paediatric Acute Decompensated Heart Failure (First Dedicated)
FOAMed & Critical Appraisal
15. SGEM Xtra — Geriatric ED Guidelines 2.0 (First GRADE-Methodology EM Subspecialty Guidelines)
Quick Hits, Action Points & Trials to Watch
GUIDELINES & UK OFFICIAL UPDATES
HSSIB · 9 APRIL 2026
Mental Health Crisis Care in EDs: HSSIB Finds Staff Have No Lawful Power to Detain — Two Safety Recommendations Issued
HSSIB has published its interim investigation report "Mental health crisis care: legislative challenges in emergency departments" — the most significant patient safety document affecting EM practice this week. The central finding is stark: there is no clear legal power to prevent a vulnerable person experiencing a mental health crisis from leaving the ED while awaiting a Mental Health Act (MHA) assessment or hospital bed. Staff are regularly forced to choose "the least harmful way to break the law." The longest reported case in the investigation involved a patient waiting 13 days in an ED for an MHA bed; waits of multiple days are now routine. People with mental health problems are twice as likely as those with physical illness to wait 12+ hours in ED, and mental health presentations account for approximately 3% of all ED attendances.
Two safety recommendations were issued: R/2026/082 directs DHSC to urgently review the legislative framework and clarify what powers ED staff have to hold patients; R/2026/083 directs CQC to produce a national position statement on existing legal powers so that staff at least know where they stand now. A second full investigation report is due summer 2026. DHSC noted £473m mental health infrastructure investment and signalled a forthcoming police powers consultation. RCEM President Dr Ian Higginson welcomed the report and called for legislative reform alongside expansion of acute mental health beds and designated places of safety.
Safety: Until legislation changes, your department has no unambiguous legal authority to detain a mental health patient who wishes to leave. Document your clinical reasoning and risk assessment meticulously for every departure against advice. Seek senior and mental health team input. If the patient lacks capacity, the Mental Capacity Act may provide a basis for short-term restriction — but this is legally contested territory. Escalate to your trust legal/governance team if in doubt.
Why it matters: This is not a new problem — but HSSIB has now placed it squarely in the patient safety record. The recommendations create accountability pathways for DHSC and CQC. Until systemic changes arrive, the burden falls on individual ED clinicians to navigate a legal gap that should never have existed. Share this report with your mental health liaison team and trust board.
Tell your department: Circulate the HSSIB report to ED leads and mental health liaison. Request a trust-level briefing on your current legal position regarding mental health patients wishing to leave before assessment. Review your department's MH crisis documentation pathway now.
UKHSA · 9 APRIL 2026
Mpox Clade Ib: UK Importation Risk Elevated to HIGH — 45 UK Cases Confirmed, Person-to-Person Spread in Europe
UKHSA's updated epidemiological overview (9 April 2026) confirms 45 UK cases of mpox clade Ib since October 2024 (to 31 March 2026). Cases have been primarily travel-linked, but UKHSA has upgraded the probability of importation from medium to HIGH following evidence of increasing person-to-person transmission in GBMSM networks across Europe and the Americas since October 2025. One recombinant clade Ib/IIb case has been identified in England in a patient with recent travel to Asia — a novel finding. Clade IIb continues at 7–110 UK cases per month with a recent uptick in northern England, totalling 4,676 cases since May 2022.
Clade Ib causes more severe illness and higher mortality than clade IIb, with greater potential for household and sexual network transmission. ED clinicians should consider mpox in any patient presenting with febrile illness plus a vesicular, pustular, or ulcerative rash — particularly with relevant travel history to central/east Africa or recent sexual contact with GBMSM networks. Suspected clade Ib cases should be isolated immediately and notified to UKHSA and the local HPT.
Safety: Place any patient with suspected mpox in a single room immediately. Use gloves, gown, and eye protection for all patient contact. Do not wait for confirmatory swab results before notifying public health. Clade Ib is a notifiable disease — report all suspected cases immediately.
Why it matters: The shift from medium to high importation risk means you are more likely to see a clade Ib case in a UK ED than at any previous point. The recombinant strain adds diagnostic complexity. Ensure your department has an up-to-date mpox triage pathway and knows how to access UKHSA's 24/7 duty HPT.
Source: UKHSA — Mpox Outbreak: Epidemiological Overview, 9 April 2026
NHS ENGLAND · 7 APRIL 2026
Martha's Rule Now in NHS Standard Contract 2026/27 — All Trusts Must Implement Three Core Components by 31 March 2027
NHS England has confirmed via the NHS Standard Contract 2026/27 (clause SC33) that Martha's Rule is now a contractual requirement for all NHS trusts and Foundation Trusts. The 31 March 2027 deadline for full implementation of all three core components — (1) a 24/7 patient/family-initiated rapid review process, (2) staff-initiated rapid review, and (3) a transparent patient safety learning system — is now binding. Named after Martha Mills, who died aged 13 following a delay in escalation to intensive care, Martha's Rule gives patients and families the explicit right to trigger an urgent clinical review from an independent team if they are concerned about deterioration that has not been acted upon.
NHS England's monthly strategic briefing (The Month, March/April 2026) confirms Martha's Rule implementation is being tracked alongside urgent and emergency care performance metrics. EDs are explicitly within scope: any patient or family member attending ED or being admitted from ED can invoke Martha's Rule if they feel their concerns are not being heard by the treating team.
Why it matters: Martha's Rule is no longer optional — it is contractual. Trusts that fail to implement by March 2027 face contractual consequences. ED teams should familiarise themselves with their trust's escalation pathway, ensure it is visible and accessible at the bedside, and understand their role when a patient or family invokes the rule. The March 2027 deadline is approaching.
Tell your department: Ask your clinical governance lead for the current status of your trust's Martha's Rule implementation. Know the number patients and families can call, and where it is displayed in your department.
Source: NHS England — The Month: March/April 2026
RCEM · 7 APRIL 2026
RCEM Scotland: Record 12-Hour Waits in February — 7,967 Patients (1 in 13), Worst Since Records Began
Citing Public Health Scotland data for February 2026, RCEM reports that 7,967 patients (1 in 13) at major Scottish EDs waited 12+ hours before admission, discharge, or transfer — the worst February on record and a staggering increase from 344 patients in February 2019. One in six patients waited 8+ hours, and only 62.4% were seen within the 4-hour standard (vs. the 95% target). RCEM Vice President Dr Fiona Hunter described the situation as "utterly dire" and called on all Scottish parties ahead of the Parliamentary elections to place ED performance at the top of the agenda.
RCEM's demands include urgent action on delayed discharges (identified as the primary driver of corridor care and 12-hour breaches), ED overcrowding, and investment in the emergency medicine workforce. The statement comes as NHS Scotland faces sustained pressure from an ageing population, social care underfunding, and unresolved workforce gaps in consultant EM posts.
Caution: The 12-hour wait data captures only the tip of the iceberg — patients who breach 8 hours, experience corridor care, or leave without being seen are not fully represented in headline statistics. Emergency care harm from crowding is largely invisible in current reporting frameworks.
Source: RCEM — "Crying out for help": Dire State of A&E Should be Top of Scottish Election Agenda
KEY JOURNAL ARTICLES & TRIALS
JAMA · 7 APRIL 2026 · PMID 41642827
OPTION Trial: Tenecteplase 4.5–24h After Non-LVO Ischaemic Stroke Improves Functional Outcomes — With a Significant sICH Signal
The OPTION trial (NCT05752916) is a phase 3, multicentre, open-label, blinded-endpoint RCT from 48 centres in China enrolling 566 patients with non-large vessel occlusion (non-LVO) acute ischaemic stroke presenting 4.5 to 24 hours after known or estimated stroke onset. Patients required evidence of salvageable tissue on CT perfusion imaging (penumbra selection) and NIHSS 6–25 (or 4–5 with disabling deficit). They were randomised to tenecteplase 0.25 mg/kg IV versus standard care (no thrombolysis).
The primary outcome — excellent functional outcome (mRS 0–1 at 90 days) — was achieved in 43.6% vs 34.2% (RR 1.28, 95% CI 1.04–1.57; P=0.02; NNT ≈ 11). The key safety signal: symptomatic intracranial haemorrhage (sICH) occurred in 2.8% vs 0% (risk difference 2.85%, P=0.004; NNH ≈ 35). Mortality did not differ significantly (5.0% vs 3.2%). REBEL EM's appraisal (9 April 2026) notes the NNT 11 vs NNH 35 as a favourable ratio, but flags that the trial was likely underpowered, conducted in a single country, and used CT perfusion selection that may not be routinely available in all UK EDs.
Why it matters: Current UK/ESO guidance restricts thrombolysis to <4.5 hours in non-LVO stroke (with some exceptions for wake-up stroke using DWI-FLAIR mismatch). OPTION is the first phase 3 RCT to show a benefit of TNK specifically in the 4.5–24h non-LVO window with penumbra selection. If replicated in international trials, this could substantially widen eligibility for thrombolysis in the very population most commonly presenting beyond the current window. The sICH rate requires shared decision-making.
Caution: This is a single-country trial (China) with a predominantly Han Chinese patient population. CT perfusion selection is required and is not universally available in UK EDs. Larger international replication trials are needed before adopting this window for routine practice. Do not extrapolate to LVO or patients ineligible for current thrombolysis criteria. The sICH rate of 2.8% — though associated with NNH 35 — represents a meaningful risk that must be disclosed.
Source: JAMA 2026;335(13):1137–1147 (PMID 41642827) · REBEL EM appraisal
ANNALS OF EMERGENCY MEDICINE · APRIL 2026 · PMID 41405523
LEGEND Trial: hs-Troponin Limit-of-Detection Strategy Reduces ED Length of Stay by 3.6 Hours — No Increase in 30-Day MACE
The LEGEND (Limit of Detection in the Emergency Department) trial is a stepped-wedge cluster RCT across four Australian EDs (n=9,944; August 2019–July 2020). The LEGEND strategy is elegantly simple: apply the hs-troponin limit of detection (LoD ≤2 ng/L) at presentation. Patients with chest pain, a troponin at or below the LoD at a single time point, and appropriate clinical risk assessment undergo shared decision-making and are considered for immediate discharge — without a second troponin at 1 or 2 hours.
Results: The LEGEND strategy reduced mean ED length of stay by 3.6 hours (95% CI 2.5–4.6h), increased the proportion discharged within 4 hours by 22.9% (95% CI 19.5–26.3%), and reduced downstream cardiac testing by 7.8% — with no increase in representations, index events, or 30-day major adverse cardiac events (MACE). Published in Annals of Emergency Medicine April 2026;87(4):424–434.
Why it matters: A 3.6-hour reduction in ED LOS per eligible patient is transformative for throughput. Most UK EDs already have hs-troponin assays; many use the 0h/1h or 0h/2h NICE-endorsed ESC pathway. LEGEND provides the strongest prospective evidence to date that a single-sample LoD approach is safe and dramatically reduces crowding. For departments already experiencing 4-hour standard pressure, this is one of the most immediately actionable trials of 2026.
Tell your department: Identify whether your current hs-troponin assay has a validated LoD. If your assay has LoD ≤2 ng/L, discuss with cardiology and governance whether a LEGEND-style single-sample pathway can be piloted. Shared decision-making documentation is essential. Check your assay's manufacturer's LoD specification today.
Source: Ann Emerg Med 2026;87(4):424–434 (PMID 41405523)
THE LANCET · 5 APRIL 2026 (PRINT) · PMID 41275876
PreMeFen Trial: Inhaled Methoxyflurane Non-Inferior to IV Morphine for Prehospital Pain at 10 Minutes
The PreMeFen trial (NCT05137184) is a phase 3, open-label, non-inferiority RCT from Norway comparing three prehospital analgesic strategies in adults with acute pain (n=338; per-protocol n=281; ground ambulance): inhaled methoxyflurane (Penthrox), intranasal fentanyl, and IV morphine. The primary outcome was pain NRS reduction at 10 minutes. Methoxyflurane was non-inferior to both intranasal fentanyl (mean NRS difference −1.33, 95% CI −2.01 to −0.64) and IV morphine (−0.36, 95% CI −1.03 to 0.31). Notably, intranasal fentanyl was not non-inferior to IV morphine at 10 minutes. Adverse events were similar across all arms (~23–24%). One serious adverse event occurred in the methoxyflurane arm (respiratory depression and loss of consciousness).
Methoxyflurane (Penthrox, the "green whistle") is already licensed in the UK and used in some prehospital services. This trial provides the first Level 1 evidence in a prehospital European ambulance context, supporting its role as a rapid-onset, non-invasive, self-administered analgesic for acute pain where IV access is delayed or unavailable.
Why it matters: For UK paramedics, methoxyflurane now has phase 3 RCT evidence supporting its use alongside or in place of IV/IN opioids for prehospital pain. The study validates the clinical decision to use it when IV access is challenging. The serious adverse event in one patient reminds us that this is not risk-free — patient monitoring remains essential.
Caution: The open-label design means placebo effect cannot be excluded. The per-protocol population (n=281) was substantially smaller than enrolled (n=338) due to a high exclusion rate. Norwegian ambulance system, staffing, and patient demographics may not fully translate to UK practice. The single serious adverse event rate (respiratory depression requiring intervention) warrants vigilance, particularly in frail or elderly patients.
Source: Lancet 2026;406(10522):2957–2967 (PMID 41275876)
NEW ENGLAND JOURNAL OF MEDICINE · 2 APRIL 2026 · PMID 41910427
SMART-DECISION: Stopping Beta-Blockers >1 Year After MI is Non-Inferior to Continuation in Selected Patients
The SMART-DECISION trial (n=2,540; 25 centres; South Korea; median follow-up 3.1 years) enrolled stable post-MI patients with preserved LVEF (≥40%) and no heart failure who had been on beta-blockers for at least 1 year. Randomised to discontinuation versus continuation. The primary composite outcome — all-cause death, recurrent MI, or heart failure hospitalisation — showed non-inferiority of discontinuation (HR 0.80, 95% CI 0.57–1.13; P=0.001 for non-inferiority). Serious adverse events were similar between groups. Published in NEJM 2026;394(13):1302–1312.
This trial joins ABYSS (France, 2024) and REDUCE (Sweden, 2024) in a growing evidence base challenging the doctrine of indefinite beta-blockade post-MI in patients who have recovered LV function and have no ongoing indication (angina, arrhythmia, HFrEF). For the ED clinician, this is most relevant when reviewing medications at discharge or managing chest pain re-presentations in post-MI patients on long-term beta-blockers who query whether they still need them.
Why it matters: Long-term beta-blocker prescribing post-MI is widespread, often reflexive, and poorly reviewed. SMART-DECISION supports stopping beta-blockers in carefully selected patients (LVEF ≥40%, no HF, no arrhythmia, >1yr post-MI) without increased risk of adverse outcomes. This changes the post-MI medication review conversation and may reduce medication burden and side effects in this population.
Caution: Do not extrapolate to patients with LVEF <40%, ongoing HF, angina, sustained arrhythmia, or recent MI (<1 year). The trial was conducted in South Korea; cardiovascular risk profiles and comorbidity patterns may differ from UK populations. Beta-blocker discontinuation should involve a cardiology or GP-led medication review — not an ED decision on a single attendance.
Source: NEJM 2026;394(13):1302–1312 (PMID 41910427)
NEW ENGLAND JOURNAL OF MEDICINE · 2 APRIL 2026 · PMID 41849741
CLOSURE-AF: Left Atrial Appendage Closure Not Non-Inferior to Best Medical Therapy in High-Risk AF
The CLOSURE-AF trial (n=912; Germany; median follow-up 3 years) enrolled AF patients at high risk of both stroke (mean CHA₂DS₂-VASc 5.2) and bleeding (mean HAS-BLED 3.0) — the very population in whom LAAC (left atrial appendage closure, e.g. Watchman device) is most commonly considered as an alternative to anticoagulation. Randomised to LAAC versus physician-directed best medical care (including optimised anticoagulation where tolerated). The composite primary outcome — stroke, systemic embolism, major bleeding, or CV/unexplained death — favoured medical therapy: LAAC 16.8 vs medical 13.3 events/100 patient-years. Non-inferiority was not achieved (P=0.44). Serious adverse events were numerically higher in the device arm (82.5% vs 77.4%).
CLOSURE-AF contradicts the premise that LAAC provides a superior safety profile to optimised medical therapy in patients considered at high bleeding risk. It joins CHAMPION-AF (2025) as a second major trial to fail to establish LAAC non-inferiority, in contrast to earlier PROTECT-AF and PREVAIL data. Published in NEJM 2026;394(13):1270–1280.
Why it matters: For ED clinicians managing AF-related stroke or major bleeding events, CLOSURE-AF is a crucial reference point. Patients who present having declined anticoagulation in favour of LAAC may not be as protected as assumed. Optimal medical management — including DOAC therapy where tolerated — remains the standard. Discuss with cardiology rather than accepting LAAC as a definitive alternative to anticoagulation.
Source: NEJM 2026;394(13):1270–1280 (PMID 41849741)
ACADEMIC EMERGENCY MEDICINE · APRIL 2026 · PMID 41947342
SPOTLESS-2: Peripheral Vasopressors Safe in Prehospital and Retrieval Medicine — 93.4% Event-Free
SPOTLESS-2 is a prospective observational cohort study (n=468; Lifeflight Medicine, Australia; April 2022–August 2023) examining the safety of peripheral vasopressor administration during prehospital and retrieval transfers. Median infusion duration was 85 minutes; 72% received noradrenaline; the most common peripheral site was the antecubital fossa (78%). Results: 93.4% of patients experienced no adverse events. Minor complications were infrequent: 3% had technical drug delivery issues, 3% had minor complications affecting care, and only 0.8% required conversion to central venous access in transit. No tissue necrosis or extravasation injuries were documented at 24-hour follow-up. Septic shock was the most common indication (47%).
These data build on existing SPOTLESS-1 and VASST series evidence supporting peripheral vasopressor use in ICU and theatre settings, now extending to the prehospital/retrieval environment where central access is logistically challenging and delays can be harmful.
Why it matters: For retrieval and HEMS teams, peripheral vasopressors can now be used with confidence in the prehospital phase without mandating central access first. Early vasopressor administration in septic shock and distributive shock saves lives — SPOTLESS-2 removes one of the remaining barriers to early initiation. Use the antecubital fossa as first-line peripheral site; monitor closely and convert if flow fails.
Source: Acad Emerg Med 2026;33(4):e70271 (PMID 41947342)
BMJ · 8 APRIL 2026 · PMID 41951238
BMJ Airway Review: Video Laryngoscopy Preferred Over Direct Laryngoscopy for RSI — Comprehensive Evidence Synthesis
This state-of-the-art review in BMJ (2026 Apr 8;393:e086612) synthesises current evidence on airway management of adults in acute care settings. Key conclusions: video laryngoscopy (VL) increases first-pass success over direct laryngoscopy (DL) for RSI and should be the preferred approach in experienced hands. Preoxygenation with NIPPV/HFNC and physiological optimisation (haemodynamic resuscitation, correction of hypoxaemia) are essential before all emergency airways. Tube placement confirmation should use waveform capnography or POCUS — clinical assessment alone is insufficient. Existing risk assessment tools for difficult airways (LEMON, DIFFICULT) have limited predictive value in isolation and should not be used to exclude VL use.
The review covers RSI drug selection (ketamine and rocuronium remain first-line in most EM contexts), adequate post-intubation analgesia and sedation (avoid oversedation while maintaining patient comfort), and early consideration of surgical airway backup. Highly practical and immediately applicable to the ED resuscitation bay.
Why it matters: This BMJ review will likely serve as a key exam reference and departmental teaching resource in 2026. It consolidates the shift away from DL as the default for ED RSI. If your department does not have VL immediately available in the resus bay, this evidence base supports making it so. Free-access FRCEM revision resource.
Source: BMJ 2026;393:e086612 (PMID 41951238)
PAEDIATRIC EMERGENCY MEDICINE
JAMA · 6 APRIL 2026 · PMID 41941197
Does This Child Have a Concussion? JAMA Rational Clinical Examination — Likelihood Ratios for Paediatric Concussion Diagnosis
This Rational Clinical Examination systematic review and meta-analysis (23 studies; 7,110 abstracts screened; patients aged 2–18 years) provides the most rigorous evidence summary to date on the diagnostic utility of individual history and examination findings in paediatric concussion. The headline finding: no single symptom or sign is sufficient to confirm or exclude concussion — structured multi-feature tools (such as SCAT6, ChildSCAT) outperform individual features.
Most useful symptoms to increase likelihood: mental fog (LR 11.8–12.0; specificity 0.96), noise sensitivity (LR 6.9), nausea (LR 6.7), light sensitivity (LR 6.4). Most useful to decrease likelihood: absence of headache (LR 0.20; sensitivity 0.74) — the most powerful single negative predictor.
Most useful signs: abnormal near-point convergence (LR 7.0), abnormal smooth pursuits (LR 6.5), saccadic abnormalities (LR 4.8). Critically, no sign had sensitivity >0.40, meaning examination findings alone cannot rule out concussion.
Why it matters: This SR directly arms ED clinicians with LR data to guide probabilistic reasoning in paediatric concussion assessment — one of the most common paediatric ED presentations. "Mental fog" is a surprisingly specific symptom (LR ~12) that is easy to ask about directly. The absence of headache is the single most useful feature for ruling out concussion (LR 0.20). Combine symptoms with validated tools and eye tracking assessment for best diagnostic performance.
Tell your department: Ask about "mental fog" specifically — it is the highest-LR positive symptom and patients (especially younger children) may not volunteer it spontaneously. Add near-point convergence testing to your paediatric concussion examination. Do not discharge based on absence of GCS change alone.
Source: JAMA 2026 Apr 6 (PMID 41941197) — Does This Child Have a Concussion?
COCHRANE DATABASE OF SYSTEMATIC REVIEWS · 2 APRIL 2026 · PMID 41925066
Cochrane Update: Standardised Neonatal Resuscitation Training Reduces 24-Hour Mortality (RR 0.73) — 528,000 Newborns, 27 Studies
This updated Cochrane review (27 studies; 528,366 newborns; updated search to June 2025; published Cochrane Database Syst Rev 2026;4(4):CD009106) examines whether standardised formal neonatal resuscitation training (SFNRT) — programmes such as Helping Babies Breathe, NLS, and NRP — reduces neonatal mortality compared to no training or basic training. The headline result: SFNRT likely decreases 24-hour mortality (RR 0.73, 95% CI 0.66–0.82; moderate certainty) and early neonatal mortality (RR 0.82, 95% CI 0.75–0.89) compared to no formal training.
Compared to basic training, SFNRT may decrease 28-day mortality (RR 0.55, 95% CI 0.33–0.91; low certainty). The evidence on whether booster training provides additional benefit beyond initial SFNRT remains very uncertain. Notably, all mortality outcome studies were conducted in low- and middle-income countries (LMICs); no data on hypoxic-ischaemic encephalopathy (HIE) outcomes were available.
Why it matters: Any ED that might receive an unexpected delivery — which is any ED — needs staff who are competent in neonatal resuscitation. This Cochrane review confirms that structured training (NLS/NRP) is the intervention with the best evidence. In the UK context, ensure all ED clinicians have current NLS certification and that neonatal resuscitation equipment is immediately accessible in the resus bay. Booster training frequency should be part of your departmental governance review.
Source: Cochrane Database Syst Rev 2026;4(4):CD009106 (PMID 41925066)
AHA SCIENTIFIC STATEMENT · 6 APRIL 2026
AHA Scientific Statement: First Dedicated Guidance on Paediatric Acute Decompensated Heart Failure — ED Assessment and Management
The American Heart Association has published the first comprehensive Scientific Statement specifically addressing acute decompensated heart failure (ADHF) in children — covering unrepaired and repaired congenital heart disease, cardiomyopathies, transplant rejection, and other acquired heart conditions (published in Circulation, 6 April 2026). Until now, paediatric heart failure guidance was largely extrapolated from adult protocols, with no dedicated document addressing the highly heterogeneous paediatric ADHF population.
Key recommendations include: a structured rapid approach integrating clinical assessment, diagnostics, and tailored therapy (diuretics, respiratory support, inotropes as appropriate) to limit deterioration in ED and ICU; prompt recognition of ADHF aetiology to guide specific management; routine mental health screening for children with congenital and acquired heart disease and their caregivers (a novel systems-level recommendation); and multidisciplinary, family-centred discharge planning. The statement explicitly supports integration of mental health professionals within the paediatric cardiac multidisciplinary team.
Why it matters: Paediatric ADHF is a rare but high-stakes ED presentation that requires immediate recognition and appropriate escalation. Previously, ED clinicians had to rely on adult heart failure frameworks or local PICU protocols. This statement provides a clear structured approach and, importantly, flags the mental health burden on children and families — an often-overlooked dimension of paediatric cardiac emergencies.
FOAMED & CRITICAL APPRAISAL
SGEM XTRA · 4 APRIL 2026
SGEM Xtra: Geriatric ED Guidelines 2.0 — First EM Subspecialty Guidelines to Use Full GRADE Methodology
The SGEM Xtra podcast (episode recorded 23 March 2026, published 4 April 2026) features Dr Christina Shenvi discussing the Geriatric Emergency Department Guidelines 2.0 (GED 2.0) — the first emergency medicine subspecialty guideline series to adopt the GRADE methodology in full. The original 2014 GED guidelines were consensus-based and lacked systematic evidence appraisal. The 2.0 update involved >60 collaborators from 23 US states and 7 countries, including emergency physicians, geriatricians, nurses, allied health professionals, methodologists, and patient representatives. Seven priority domains were identified: delirium, dementia, falls, frailty, medication management, palliative care, and elder abuse.
Fourteen planned systematic reviews/meta-analyses and 6–7 clinical practice guidelines are being developed (accessible via the GEAR 2.0 website). The key insight from the episode: GRADE methodology enables transparent, reproducible, and patient-centred recommendations that can withstand scrutiny — and the GED 2.0 model is explicitly designed as a blueprint for other EM subspecialties (toxicology, critical care, ultrasound). Implementation strategies include workshops, webinars, and social media knowledge translation campaigns.
Why it matters: Older adults are the fastest-growing demographic in UK EDs. GED 2.0 is the first rigorously developed, GRADE-quality clinical guidance tool specifically for geriatric EM — addressing the seven domains most commonly implicated in adverse outcomes in this population. Watch the GEAR 2.0 website for guideline releases; this is essential reading for any ED that sees elderly patients (i.e., all of them).
Source: SGEM Xtra — GED 2.0 Guidelines (4 April 2026)
QUICK HITS
EVERDAC Trial (REBEL EM, 6 Apr): In 1,010 patients with circulatory shock, non-invasive brachial cuff BP monitoring was non-inferior to arterial line for 28-day mortality, with fewer procedural complications. A 14.7% rescue arterial line rate applied when NIBP failed. Excludes BMI >40 and trauma/surgical patients. REBEL EM →
St Emlyn's TTL Tip 9 — Chest Drain Before CT (9 Apr): Simon Carley's framework for the most contested trauma decision: drain if haemodynamically compromised, unstable, ventilated, or bilateral pneumothorax; go straight to CT if stable with minimal symptoms; in between — communicate, take drain equipment, and make the decision explicit. The ongoing UK RCT CoMiTED will inform future guidance. St Emlyn's →
First10EM — BP Targets in Spinal Cord Injury (6 Apr): Critical appraisal of the first RCT on BP targets in acute SCI (n=92, stopped early). Augmented MAP >85–90 mmHg showed no neurological benefit and significantly more respiratory complications (78% vs 39%). Conventional MAP 65–70 mmHg remains standard. First10EM →
Missed Carbidopa-Levodopa in ED (Acad Emerg Med, Apr): Carbidopa-levodopa was administered in only 32.3% of eligible ED encounters in Parkinson's patients; mean time to administration was 6 hours 11 minutes. Missed dopaminergic medications cause rigidity, aspiration risk, and acute akinetic crisis. Review your department's PD medication protocol and consider PDMED red bag systems. PMID: 41910596
LITFL — Foley Balloon Tamponade for Junctional Haemorrhage (9 Apr): Kane Guthrie's guide to using a 22Fr 3-way Foley catheter for temporising control of catastrophic junctional haemorrhage (neck, axilla, groin). Evidence: Scriba et al. — 95 cases at Groote Schuur, 96.8% haemostasis achieved; 81% performed pre-tertiary. Bridge to CTA/surgery, not definitive. LITFL →
Sepsis Host Resistance/Damage Biomarkers (ICM, 7 Apr): Prospective cohort (n=444, enrolled within 6h of ED arrival). "Damage" biomarker signature independently associated with 90-day mortality (aOR 1.70). SENECA subtyping: δ-type = highest damage + lowest tolerance; α-type = lowest damage + best outcome. Sets stage for biomarker-guided sepsis treatment trials. PMID: 41944864
DFTB — PCCS Wellbeing Toolkit for UK PICUs (7 Apr): Overview of the Paediatric Critical Care Society Wellbeing Toolkit — a freely accessible, peer-developed resource across 10 wellbeing domains for PICU staff. Addresses burnout, compassion fatigue, and moral distress post-COVID. Relevant to all paediatric acute care teams. DFTB →
NICE Cost-Effectiveness Thresholds Raised (2 Apr): NICE has implemented new cost-effectiveness thresholds for technology appraisals: the standard threshold rises from £20,000–£30,000 to £25,000–£35,000 per QALY. Expected to approve an additional 3–5 new medicines/indications per year. Affects the pipeline of drugs becoming available on the NHS. NICE →
TRIALS TO WATCH
ON THE HORIZON
PARAMEDIC-3 — Prehospital adrenaline timing in OHCA: optimal time-to-first-adrenaline dose in out-of-hospital cardiac arrest. UK-based multicentre RCT. Results expected mid-2026. High relevance for HEMS teams and ambulance service protocols.
CoMiTED — Chest drain timing in thoracic trauma: UK RCT examining the safety of deferring chest drain insertion to post-CT vs immediate pre-CT drainage in haemodynamically stable patients with suspected haemo/pneumothorax. Referenced this week by St Emlyn's TTL Tip 9. Will provide UK-specific Level 1 evidence for this contested decision.
OPTION Extension Studies — Following this week's OPTION trial result, confirmatory international trials in the late-window thrombolysis space are expected. Watch for multi-country replication designed to address the generalisability gap of the China-only OPTION cohort. Essential before this window becomes routine UK practice.
ACTION POINTS THIS WEEK
| 1 | Know your legal position on mental health patients in the ED. Read the HSSIB interim report and request a trust-level briefing on your legal powers to prevent a patient leaving during MHA assessment. Document all departures against advice meticulously. |
| 2 | Update your mpox triage pathway. UKHSA has raised clade Ib importation risk to HIGH. Ensure your department has a current triage algorithm for febrile rash presentations, including a pathway to the 24/7 UKHSA HPT. Review isolation room availability. |
3
Check your Martha's Rule implementation status. The 31 March 2027 contractual deadline is less than 12 months away. Ask your clinical governance lead: does your trust have all three components in place? Is it visible to patients and families in your ED?
| 4 | Investigate your hs-troponin assay's limit of detection. If your assay has LoD ≤2 ng/L, explore with cardiology and governance whether a LEGEND-style single-sample discharge pathway is feasible. A 3.6-hour LOS reduction per eligible patient is a powerful lever against 4-hour standard pressure. |
| 5 | Audit Parkinson's disease medication administration in your ED. LEGEND showed 32% compliance in comparable EDs. Is carbidopa-levodopa on your medication checklist for all PD admissions? Consider implementing a PD PDMED red bag protocol if not already in place. |
| 6 | Confirm video laryngoscopy availability in your resus bay. The BMJ airway review confirms VL increases first-pass intubation success and should be the default for RSI. If VL is not immediately at the bedside in your resus bay, escalate as a clinical risk. |
| 7 | Add "mental fog" to your paediatric concussion clerking. LR ≈ 12 makes it the highest-specificity single concussion symptom. Ask it directly ("Do you feel foggy or slow?"). Add near-point convergence to your examination. Do not rely on GCS alone for paediatric concussion assessment. |
SOURCES CHECKED THIS WEEK HSSIB · RCEM · UKHSA · NHS England · NICE · MHRA · DHSC · RCOG · RCPCH · RCUK · PubMed (JAMA, NEJM, Lancet, Ann Emerg Med, BMJ, Acad Emerg Med, Intensive Care Med, Cochrane, Crit Care Med) · medRxiv · ClinicalTrials.gov · First10EM · EMCrit · REBEL EM · St Emlyn's · SGEM · Core EM · DFTB · LITFL · BestBETs · The Bottom Line · RCEM Learning · AHA/ACC · SCCM/SSC · ESC · EAST · NAEMSP · ILCOR Next briefing: Week of 16 April 2026 | Research window: 10–16 April 2026
Jake Turner · Emergency Medicine, UK
Curated with the assistance of AI (Perplexity). All content editorially reviewed by the author. Sources linked throughout. Disclaimer: This newsletter is for educational and informational purposes only and does not constitute clinical advice. Always exercise independent clinical judgement and consult local protocols and senior colleagues. Evidence summaries are accurate at time of writing but the evidence base evolves — check primary sources before implementing any change. The author accepts no liability for clinical decisions made on the basis of this content.